Selinexor in patients with advanced and recurrent endometrial cancer

子宫内膜癌 医学 癌症研究 癌症 化疗 肿瘤科 疾病 内科学
作者
Giorgio Bogani,Bradley J. Monk,Robert L. Coleman,Ignace Vergote,Ana Oakin,Isabelle Ray‐Coquard,Andrea Mariani,Giovanni Scambia,Francesco Raspagliesi,Bruno Bolognese
出处
期刊:Current Problems in Cancer [Elsevier BV]
卷期号:47 (6): 100963-100963 被引量:8
标识
DOI:10.1016/j.currproblcancer.2023.100963
摘要

Selinexor is an oral inhibitor of the nuclear export protein called Exportin 1 (XPO1) with demonstrated antitumor activity in hematological and solid tumors. Selinexor, blocking XPO1, induces nuclear localization of tumor suppressor proteins (including p53, p73, BRCA1, and pRB), leading to the selective induction of apoptosis, and inhibition of DNA damage repair proteins. XPO1 overexpression is common in endometrial cancers. Phase I and II trials reported the antitumor activity of selinexor in patients with endometrial carcinoma. The preliminary results of the phase III Selinexor in ENDOmetrial Cancer (SIENDO/ENGOT-EN5/GOG-3055) trial supported the use of selinexor as maintenance therapy in advanced endometrial cancer patients achieving at least partial response after a minimum of 12 weeks of first-line platinum-based chemotherapy. Selinexor maintenance resulted in a (nonsignificant) 30% reduction in the risk of disease progression or death. Looking at the endometrial cancer molecular subgroup characterized by TP53 wild type, the antitumor activity of selinexor seemed more pronounced, resulting in approximately a 60% reduction in the risk of disease progression or death. The SIENDO and the XPORT-EC trials will clarify the benefits and risks of adding selinexor as a first-line chemotherapy maintenance treatment in all-comer and TP53 wild-type endometrial cancers. Preclinical data highlights the potential for selinexor to be synthetically lethal with PARP inhibitors and may also plan a role in overcoming acquired resistance to those therapies. Therefore, new possible combinations with PARP inhibitors and should be evaluated. Furthermore, the combination of selinexor plus immune checkpoint inhibitors deserves further investigation in clinical trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
淘宝叮咚发布了新的文献求助10
刚刚
1秒前
2秒前
打打应助CC采纳,获得10
2秒前
4秒前
5秒前
小强123发布了新的文献求助10
6秒前
7秒前
追寻易云发布了新的文献求助10
7秒前
明理采珊发布了新的文献求助10
8秒前
8秒前
小马甲应助lqy采纳,获得10
8秒前
执着的完成签到,获得积分10
9秒前
10秒前
10秒前
11秒前
liuxuying发布了新的文献求助10
11秒前
欢喜曼岚完成签到,获得积分10
13秒前
13秒前
芬达发布了新的文献求助10
14秒前
小强123完成签到,获得积分10
15秒前
16秒前
17秒前
18秒前
上官若男应助西西采纳,获得10
18秒前
18秒前
卡卡发布了新的文献求助10
18秒前
追寻易云完成签到,获得积分10
18秒前
CipherSage应助Bean采纳,获得10
21秒前
dangan发布了新的文献求助20
22秒前
happyness发布了新的文献求助10
22秒前
完美世界应助林林采纳,获得10
23秒前
24秒前
桐桐应助俭朴的不可采纳,获得10
25秒前
赘婿应助XYX采纳,获得10
25秒前
Bean完成签到,获得积分10
26秒前
02Zhu完成签到,获得积分10
27秒前
happyness完成签到,获得积分10
27秒前
罗咩咩发布了新的文献求助10
28秒前
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975953
求助须知:如何正确求助?哪些是违规求助? 3520269
关于积分的说明 11201866
捐赠科研通 3256738
什么是DOI,文献DOI怎么找? 1798436
邀请新用户注册赠送积分活动 877578
科研通“疑难数据库(出版商)”最低求助积分说明 806464